COSM

Cosmos Health received Nasdaq notices regarding non-compliance but later reported regaining compliance. The company's shares slid in May 2026 as its Q4 2025 earnings miss widened to 660%, posting a loss per share of $0.31. In April 2026, Cosmos Health reported record full-year 2025 revenue of $65.3 million, a 20% increase year-over-year. Cosmos Health announced the completion of Phase 1 execution for Liv18™, with production commencing in April 2026 in the U.S. and projected to generate over $5 million in annual revenue. The company also projected over $2.5 million in incremental annual revenue from Cur18 in the United States and announced the planned U.S. market launch of Cur18b in April 2026. Cosmos Health advanced its AI investments to enhance efficiency, reduce costs, improve customer experience, and drive sales growth. In February 2026, Cosmos Health expanded its Bitcoin holdings to support its long-term digital asset strategy. In November 2025, Cosmos Health reported Q3 2025 adjusted EPS of -$0.17.